BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting

Table 1 Properties of BCMA-targeted CAR-T cell therapies in MM

Author	Agent	Clinical Trial Identifier	Phase	Target	Co-stimulatory domain/signaling domain	Mechanism	scFV	Cell source	References
Munshi et al.	ide-cel	NCT03361748	2	BCMA	4-1BB/CD3ζ	CAR-T	Chimeric mouse	Autologous	[1]
Mi et al.	cilta-cel	NCT03758417	2	Dual-binding BCMA	4-1BB/CD3ζ	CAR-T	Chimeric llama	Autologous	[3]
Mi et al.	LCAR-B38M CAR-T	NCT03090659	1	Dual-binding BCMA	4-1BB/CD3ζ	CAR-T	Chimeric llama	Autologous	[4, 5]
Lin et al.	cilta-cel	NCT03548207	1b/2	Dual-binding BCMA	4-1BB/CD3ζ	CAR-T	Chimeric llama	Autologous	[2, 6]
Rodriguez-Otero et al.	ide-cel	NCT03651128	3	BCMA	4-1BB/CD3ζ	CAR-T	Chimeric mouse	Autologous	[7]
Dhakal et al.	cilta-cel	NCT04181827	3	Dual-binding BCMA	4-1BB/CD3ζ	CAR-T	Chimeric llama	Autologous	[8, 9]
Sperling et al.	PHE885	NCT04318327	1	BCMA	4-1BB/CD3ζ	CAR-T	Human	Autologous	[10]
Du et al.	GC012F	NCT04236011; NCT04182581	1	BCMA/CD19	4-1BB/CD3ζ	CAR-T	Not specified	Autologous	[11]

BCMA B-cell maturation antigen, CAR chimeric antigen receptor, scFV single-chain variable fragment, cilta-cel ciltacabtagene autoleucel, ide-cel idecabtagene vicleucel

ISSN: 1756-8722